文献速递神经免疫认知障碍与痴呆

奥瑞利珠单抗单药治疗进展型多发性硬化患者发生进行性多灶性白质脑病

Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy.
PubMed 文献 · JAMA Neurol · 2021-01-01

本文报告一例78岁进展型多发性硬化患者在接受奥瑞利珠单抗单药治疗2年后发生进行性多灶性白质脑病(PML)的病例。脑脊液JC病毒载量1000 copies/mL,确诊时存在2级淋巴细胞减少。尽管停用奥瑞利珠单抗并尝试帕博利珠单抗治疗,患者仍快速恶化并死亡,尸检证实PML。

要点

  • 奥瑞利珠单抗单药治疗期间可发生PML,即使无既往免疫调节治疗史。
  • 老年患者可能因年龄相关免疫衰老而感染风险更高。
  • 开始奥瑞利珠单抗前应充分权衡风险与获益,尤其是高危患者。

核心结论

  • PML的发生可能源于奥瑞利珠单抗的免疫调节作用及年龄相关免疫衰老。

研究设计与样本

  • 来自学术医疗中心的单例病例报告,患者为78岁进展型多发性硬化男性,接受奥瑞利珠单抗单药治疗2年。

主要发现

  • 患者表现为进行性视觉障碍和意识模糊2周,检查示右侧同向性偏盲,MRI示左侧顶叶非强化病灶增大但无占位效应。
  • 脑脊液JC病毒载量1000 copies/mL,确诊PML;诊断时血液检查示2级淋巴细胞减少,绝对淋巴细胞计数710/μL,CD4 294/μL,CD8 85/μL,CD19 1/μL,CD4/CD8比值3.45,HIV血清学阴性。
  • 回顾性绝对淋巴细胞计数显示奥瑞利珠单抗治疗前存在间歇性1级淋巴细胞减少(范围800-1200/μL)。
  • 停用奥瑞利珠单抗并开始超说明书使用帕博利珠单抗后,患者仍快速恶化并死亡,尸检证实PML。

临床怎么用

  • 使用奥瑞利珠单抗前应与患者充分讨论PML等感染风险与获益,尤其对老年等高危患者。
  • 治疗期间需关注淋巴细胞计数变化,出现新发神经系统症状时应警惕PML并及时评估。

局限性

  • 本文为单例病例报告,不能确立因果关系或评估发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus that has no proven effective treatment. Although rare cases of PML have occurred with other anti-CD20 therapies, there had been no prior cases associated with ocrelizumab. OBJECTIVE: To report the first ever case of PML occurring with ocrelizumab monotherapy in a patient with progressive multiple sclerosis without prior immunomodulation. DESIGN, SETTING, AND PARTICIPANT: This case was reported from an academic medical center. The patient had multiple sclerosis while receiving ocrelizumab monotherapy. EXPOSURES: Ocrelizumab monotherapy. RESULTS: A 78-year-old man with progressive multiple sclerosis treated with ocrelizumab monotherapy for 2 years presented with 2 weeks of progressive visual disturbance and confusion. Examination demonstrated a right homonymous hemianopia, and magnetic resonance imaging revealed an enlarging nonenhancing left parietal lesion without mass effect. Cerebrospinal fluid revealed 1000 copies/mL of JC virus, confirming the diagnosis of PML. Blood work on diagnosis revealed grade 2 lymphopenia, with absolute lymphocyte count of 710/μL, CD4 of 294/μL (reference range, 325-1251/μL), CD8 of 85/μL (reference range, 90-775/μL), CD19 of 1/μL, preserved CD4/CD8 ratio (3.45), and negative HIV serology. Retrospective absolute lymphocyte count revealed intermittent grade 1 lymphopenia that preceded ocrelizumab (absolute lymphocyte count range, 800-1200/μL). The patient's symptoms progressed over weeks to involve bilateral visual loss, right-sided facial droop, and dysphasia. Ocrelizumab was discontinued and off-label pembrolizumab treatment was initiated. The patient nevertheless declined rapidly and ultimately died. PML was confirmed at autopsy. CONCLUSIONS AND RELEVANCE: In this case report, PML occurrence was likely a result of the immunomodulatory function of ocrelizumab as well as age-related immunosenescence. This case report emphasizes the importance of a thorough discussion of the risks and benefits of ocrelizumab, especially in patients at higher risk for infections such as elderly patients.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Patel A, Sul J, Gordon ML, et al. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol. 2021. PMID: 33724354. doi:10.1001/jamaneurol.2021.0627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。